

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 12b-25

SEC FILE NUMBER  
333-88480

NOTIFICATION OF LATE FILING

CUSIP NUMBER  
67778H200

(Check one):  Form 10-K  Form 20-F  Form 11-K  Form 10-Q  Form 10-D  Form N-SAR  
 Form N-CSR  
For Period Ended: September 30, 2014  
 Transition Report on Form 10-K  
 Transition Report on Form 20-F  
 Transition Report on Form 11-K  
 Transition Report on Form 10-Q  
 Transition Report on Form N-SAR  
For the Transition Period Ended: \_\_\_\_\_

*Read Instruction (on back page) Before Preparing Form. Please Print or Type.*

**Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I – REGISTRANT INFORMATION**

Ohr Pharmaceutical, Inc.  
Full Name of Registrant

Former Name if Applicable

800 3rd Avenue, 11th Floor,  
Address of Principal Executive Office (Street and Number)

New York, NY 10022  
City, State and Zip Code

**PART II – RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

**PART III - NARRATIVE**

The Registrant's Annual Report on Form 10-K could not be filed within the prescribed time period due to delays, which could not be eliminated without unreasonable effort or expense, associated with preparation of the Registrant's financial statements. The Registrant anticipates filing its Form 10-K within the fifteen calendar day extension period provided under Rule 12b-25.

**PART IV – OTHER INFORMATION**

(1) Name and telephone number of person to contact in regard to this notification  
Sam Backenroth, CFO 212 682-3545  
(Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes  No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  
Yes  No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

For the fiscal year ended September 30, 2014, the Company had zero revenues and operating expenses of approximately \$9.1 million for losses of approximately \$9.1 million, as compared to zero revenues and operating expenses of \$4,620,916 for losses of \$5,652,488 for the fiscal year ended September 30, 2013. The increased losses and expenses resulted from an increase in development activity, including clinical and preclinical studies.

---

**Ohr Pharmaceutical, Inc.**  
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 15, 2014

By: /s/ Sam Backenroth  
Sam Backenroth, Chief Financial Officer  
(Principal accounting and financial officer)